GenCTX provides a synthetic biology platform that programs cells with genetic circuits to detect DNA damage and stress signals, then execute precise therapeutic actions such as suicide genes, CRISPR payloads, or immune stimulators only in malignant cells. The modular sensor‑logic‑effector architecture includes a built‑in negative regulator to keep circuits inactive in healthy cells, enabling safe, self‑regulated gene therapies for hard‑to‑treat cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often lack specificity, leading to damage of healthy cells and limited effectiveness against tumors that develop resistance, metastasize, or recur. The underlying genomic instability of cancer cells is not directly targeted, making it difficult to achieve precise, context‑dependent treatment.
Solution
GenCTX engineers synthetic genetic circuits that embed programmable logic within cells to sense molecular cues of DNA damage and stress, interpret the cellular context, and trigger therapeutic actions only in malignant cells. By coupling sensor modules to a decision layer, the platform determines whether a cell should repair, pause division, or undergo controlled removal. Therapeutic effectors such as suicide genes, CRISPR payloads, or immune stimulators are activated exclusively when persistent genomic instability is detected, minimizing off‑target effects. The system incorporates a natural negative regulator that keeps the circuit silent in healthy cells, ensuring safety. This approach transforms cancer’s genomic instability into a selectable vulnerability, enabling precise, self‑regulated gene therapies for hard‑to‑treat malignancies.
Target Audience
Primary customers are biotech and pharmaceutical companies developing gene‑therapy solutions for aggressive cancers such as small‑cell lung cancer, as well as academic and research institutions focused on synthetic biology–based therapeutic platforms.
Features
- Modular sensor suite that reads DNA‑damage signals and intracellular stress markers with high specificity
- Programmable logic layer that evaluates sensor inputs to decide between repair, cell‑cycle pause, or induced cell death
- Therapeutic effector library including suicide genes, CRISPR‑based payloads, and immune‑stimulating molecules activated only in unstable cells
- Built‑in negative regulator that suppresses circuit activity in normal, stable cells to prevent off‑target expression
- Reconfigurable architecture allowing rapid recombination of sensors, regulators, and effectors for different cancer types
- Predictive modeling framework that forecasts circuit behavior and optimizes design cycles through protein engineering and empirical validation